Comparison Overview

Spectrogon AB

VS

CytoViva, Inc

Spectrogon AB

Tillverkarvägen 1, Täby, Stockholm County SE-18766, SE
Last Update: 2025-05-02 (UTC)
View Profile
Between 750 and 799
http://www.spectrogon.com

Spectrogon manufactures and develops optical filters, thin film coatings, and holographic diffraction gratings. Spectrogon derives its origin partly from research conducted at the Royal Institute of Technology in Stockholm, and partly from research and development projects at AGA AB, a former major Swedish industrial group. In 1980 we became AGA Optical, which eventually became Spectrogon in 1984. Spectrogon AB became an independent company 1991. With over 90 % in export, our most important markets are Western Europe and North America. More than 80 % of invoiced sales go to OEM in specialised electro-optics markets. These markets include: instrumentation for medical diagnostics, industrial process control, robotics, environmental measurements, optical communications and other related instrumentation. Show more Show less

NAICS: 541713
NAICS Definition: Research and Development in Nanotechnology
Employees: 51-200
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0
View Profile

CytoViva, Inc

570 Devall Drive, Auburn, AL, 36832, US
Last Update: 2025-03-14 (UTC)
Between 700 and 749
http://www.cytoviva.com

CytoViva® is a leading provider of advanced optical microscopy and hyperspectral imaging technologies. These technologies have been specifically designed for nanomaterials, nanomedicine and life science related research. CytoViva's patented illumination technology integrates onto a standard optical microscope, creating a high signal-to-noise, darkfield-based image. This specialized capability enables fast observation of a wide range of nanomaterials and pathogens along with unlabeled or fluorescently labeled cells and tissue. The CytoViva Hyperspectral Imaging System attaches to the CytoViva Microscope System. It serves to quantify the presence of a wide range of nanomaterials in cells and tissue or in composites. The system captures the VNIR (400-1000nm) or SWIR (900-1700nm) spectrum within each pixel of the scanned field of view. Advanced analytical software then provides detailed spectral analysis of the scanned materials. For additional information, contact us by email at [email protected] or by phone at 1-888-737-3130.

NAICS: 541
NAICS Definition:
Employees: 9
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/spectrogon-ab.jpeg
Spectrogon AB
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/cytoviva-inc.jpeg
CytoViva, Inc
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Spectrogon AB
100%
Compliance Rate
0/4 Standards Verified
CytoViva, Inc
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Nanotechnology Research Industry Average (This Year)

No incidents recorded for Spectrogon AB in 2025.

Incidents vs Nanotechnology Research Industry Average (This Year)

No incidents recorded for CytoViva, Inc in 2025.

Incident History — Spectrogon AB (X = Date, Y = Severity)

Spectrogon AB cyber incidents detection timeline including parent company and subsidiaries

Incident History — CytoViva, Inc (X = Date, Y = Severity)

CytoViva, Inc cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/spectrogon-ab.jpeg
Spectrogon AB
Incidents

No Incident

https://images.rankiteo.com/companyimages/cytoviva-inc.jpeg
CytoViva, Inc
Incidents

No Incident

FAQ

Spectrogon AB company demonstrates a stronger AI Cybersecurity Score compared to CytoViva, Inc company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, CytoViva, Inc company has disclosed a higher number of cyber incidents compared to Spectrogon AB company.

In the current year, CytoViva, Inc company and Spectrogon AB company have not reported any cyber incidents.

Neither CytoViva, Inc company nor Spectrogon AB company has reported experiencing a ransomware attack publicly.

Neither CytoViva, Inc company nor Spectrogon AB company has reported experiencing a data breach publicly.

Neither CytoViva, Inc company nor Spectrogon AB company has reported experiencing targeted cyberattacks publicly.

Neither Spectrogon AB company nor CytoViva, Inc company has reported experiencing or disclosing vulnerabilities publicly.

Neither Spectrogon AB nor CytoViva, Inc holds any compliance certifications.

Neither company holds any compliance certifications.

Neither Spectrogon AB company nor CytoViva, Inc company has publicly disclosed detailed information about the number of their subsidiaries.

CytoViva, Inc company employs more people globally than Spectrogon AB company, reflecting its scale as a Nanotechnology Research.

Neither Spectrogon AB nor CytoViva, Inc holds SOC 2 Type 1 certification.

Neither Spectrogon AB nor CytoViva, Inc holds SOC 2 Type 2 certification.

Neither Spectrogon AB nor CytoViva, Inc holds ISO 27001 certification.

Neither Spectrogon AB nor CytoViva, Inc holds PCI DSS certification.

Neither Spectrogon AB nor CytoViva, Inc holds HIPAA certification.

Neither Spectrogon AB nor CytoViva, Inc holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

The Bold Page Builder plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the ‘percentage’ parameter in all versions up to, and including, 5.4.5 due to insufficient input sanitization and output escaping. This makes it possible for authenticated attackers, with Contributor-level access and above, to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 6.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:L/A:N
References
Description

The ComboServlet in Liferay Portal 7.4.0 through 7.4.3.111, and older unsupported versions, and Liferay DXP 2023.Q4.0 through 2023.Q4.2, 2023.Q3.1 through 2023.Q3.5, 7.4 GA through update 92, 7.3 GA through update 35, and older unsupported versions does not limit the number or size of the files it will combine, which allows remote attackers to create very large responses that lead to a denial of service attack via the URL query string.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary directories on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and create arbitrary directories on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary files on the target machine.

Published
Date
2025-10-23
Updated
Date
2025-10-23
Risk Information
cvss3
Base: 7.5
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:H
cvss4
Base: 8.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:H/SC:N/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References